Barrington Research Reaffirms Outperform Rating for LeMaitre Vascular (NASDAQ:LMAT)

LeMaitre Vascular (NASDAQ:LMAT)‘s stock had its “outperform” rating restated by analysts at Barrington Research in a research report issued on Friday,Benzinga reports. They currently have a $95.00 target price on the medical instruments supplier’s stock. Barrington Research’s price target would suggest a potential upside of 2.22% from the stock’s previous close.

Several other brokerages have also issued reports on LMAT. Wells Fargo & Company cut their price objective on shares of LeMaitre Vascular from $97.00 to $93.00 and set an “equal weight” rating on the stock in a report on Friday, November 7th. Roth Mkm reiterated a “buy” rating and issued a $108.00 price target on shares of LeMaitre Vascular in a report on Wednesday, November 5th. Wall Street Zen cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Saturday, December 6th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $95.00 price objective on shares of LeMaitre Vascular in a research report on Monday, November 10th. Finally, Zacks Research lowered LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 1st. Four investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $100.20.

LeMaitre Vascular Stock Up 1.2%

Shares of LeMaitre Vascular stock opened at $92.94 on Friday. The company has a debt-to-equity ratio of 0.44, a current ratio of 13.58 and a quick ratio of 11.45. LeMaitre Vascular has a 1 year low of $71.42 and a 1 year high of $105.55. The firm’s 50-day moving average is $85.54 and its two-hundred day moving average is $88.16. The stock has a market cap of $2.11 billion, a price-to-earnings ratio of 40.06, a PEG ratio of 2.06 and a beta of 0.72.

Hedge Funds Weigh In On LeMaitre Vascular

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Advisors Asset Management Inc. grew its position in LeMaitre Vascular by 3.0% during the 2nd quarter. Advisors Asset Management Inc. now owns 4,111 shares of the medical instruments supplier’s stock worth $341,000 after purchasing an additional 118 shares during the last quarter. Illinois Municipal Retirement Fund lifted its stake in shares of LeMaitre Vascular by 1.1% during the fourth quarter. Illinois Municipal Retirement Fund now owns 11,171 shares of the medical instruments supplier’s stock worth $906,000 after buying an additional 123 shares during the period. NewEdge Advisors LLC grew its holdings in shares of LeMaitre Vascular by 4.6% during the fourth quarter. NewEdge Advisors LLC now owns 3,158 shares of the medical instruments supplier’s stock valued at $256,000 after buying an additional 139 shares during the last quarter. State of Alaska Department of Revenue grew its holdings in shares of LeMaitre Vascular by 1.2% during the fourth quarter. State of Alaska Department of Revenue now owns 11,986 shares of the medical instruments supplier’s stock valued at $971,000 after buying an additional 147 shares during the last quarter. Finally, Johnson Investment Counsel Inc. increased its position in shares of LeMaitre Vascular by 0.5% in the 3rd quarter. Johnson Investment Counsel Inc. now owns 29,792 shares of the medical instruments supplier’s stock valued at $2,607,000 after acquiring an additional 153 shares during the period. 84.64% of the stock is owned by hedge funds and other institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.